Apexigen, BMS to combine CD40 and anti-CSF-1 drugs with Opdivo in new study

Apexigen and BMS hope a combination of CD40 activation and CSF-1 inhibition can turn cold tumors hot, triggering T cell responses in the tumor microenvironment. (Pixabay)

Apexigen has begun collaborating with Yale Cancer Center on an early-stage clinical trial that combines the biotech’s APX005M CD40 activator with Bristol-Myers Squibb’s Opdivo and cabiralizumab, an investigational anti-CSF-1 antibody, in patients with advanced solid tumors.

The phase 1/1b study plans to enroll 120 patients with metastatic non-small cell lung cancer, metastatic melanoma and renal cell carcinoma whose disease has progressed following an anti-PD-1/PD-L1 therapy.

BMS, looking for new ways to extend the effectiveness of its flagship checkpoint inhibitor, will provide a portion of the funding, as well as supply Opdivo (nivolumab) and cabiralizumab, which is being co-developed with Five Prime Therapeutics in a $1.74 billion deal.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

According to the San Carlos, California-based Apexigen, preclinical data and mouse model studies from Yale researchers and others have shown treatment with a combination of CD40 activation and inhibition of the CSF-1 receptor can modify tumor-associated macrophages and activate T cells in the tumor microenvironment and launching an immune response.

RELATED: Five Prime founder Williams makes way for new CEO

“There is an urgent need to find effective therapies for the growing number of patients who have not responded to checkpoint inhibitors,” Apexigen President and CEO Xiaodong Yang, M.D., said in a statement.

“CD40 has a fundamental role in the activation of both innate and adaptive immunity, and we believe that CD40 activation by APX005M will become a key component of a number of promising new I-O therapeutic regimens for treating cancer patients,” Yang said.

RELATED: Bristol-Myers Squibb makes history with major multibillion-dollar Nektar drug pact

Apexigen recently brought on BMS’ former director of in vivo studies, Frances Rena Bahjat, as its new VP of discovery research. Apexigen’s discovery platform focuses on rabbit monoclonal antibodies and mutational lineage-guided humanization, producing seven candidates including its lead program, APX005M, which is also being studied in a phase 2 trial at the University of California, San Francisco.

Suggested Articles

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.

Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.

Shares in Aerpio Pharmaceuticals were more than halved in early trading this morning after it announced the failure of its leading drug candidate.